The second Affiliated Hospital of Guangzhou Medical University
The second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 2 | 2026-09-28 | NCT06979336 | |
| Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-08-11 | NCT06904183 | |
| Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Not stated | 2026-07-31 | NCT07442045 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Recruiting | Phase 1 / Phase 2 | 2026-07-22 | NCT07717905 | |
| Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis | bronchial disorder, bronchiectasis, respiratory system disorder | Not yet recruiting | Phase 2 | 2026-04-13 | NCT07523165 | |
| A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 3 | 2025-11-05 | NCT05837897 | |
| Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2025-04-29 | NCT06904196 | |
| DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2025-02-20 | NCT06397235 | |
| Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 3 | 2025-01-29 | NCT06492395 | |
| Y-90 SIRT for Unresectable HCC Larger Than 7cm | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2025-01-28 | NCT06707233 | |
| Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2024-08-21 | NCT04770207 | |
| Stem Cell Derived Exome for Treatment of Diabetic Foot | Diabetes Complications, Diabetic Foot, Foot Ulcer, Leg Ulcer, Skin Ulcer, Skin and Connective Tissue Diseases, cardiovascular disorder, diabetes mellitus, diabetic neuropathy, diabetic peripheral angiopathy, endocrine system disorder, skin disorder, vascular disorder | Not yet recruiting | Phase 1 / Phase 2 | 2024-06-28 | NCT06480123 | |
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, endocrine system disorder, epithelial neoplasm, liver cancer, liver disorder, lung cancer, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, pancreas disorder, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2024-06-26 | NCT06196294 | |
| Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2024-06-26 | NCT04952272 | |
| Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I | Anti-cancer Cell Immunotherapy; T Cell and NK Cell | Recruiting | Phase 1 / Phase 2 | 2024-06-26 | NCT03882840 | |
| Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 | 2024-06-25 | NCT05779917 | |
| Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast cancer, breast disorder, breast neoplasm, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, head and neck cancer, intestinal disorder, liver cancer, liver disorder, lung cancer, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, stomach disorder, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2024-06-25 | NCT05187338 | |
| Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2024-06-25 | NCT04803318 | |
| GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Simpson-Golabi-Behmel syndrome, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, squamous cell lung carcinoma | Recruiting | Phase 1 | 2024-06-25 | NCT03198546 | |
| GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers | Neoplasms by Site, Thoracic Neoplasms, cancer, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2024-06-25 | NCT03198052 | |
| iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray | Neoplasms by Site, Thoracic Neoplasms, cancer, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2024-06-25 | NCT03192501 | |
| Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2024-05-07 | NCT06397222 | |
| SIRT for Potentially Resectable HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Not applicable | 2023-09-14 | NCT05994859 | |
| Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC | Hepatocellular Carcinoma Non-resectable | Recruiting | Phase 3 | 2023-08-14 | NCT05985798 | |
| Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 3 | 2023-05-31 | NCT05608200 |